International audienceOBJECTIVE: To examine the association of lipid-lowering drugs, change in diet and physical activity with a decline in low-density lipoprotein (LDL) cholesterol in middle age. DESIGN: A prospective cohort study. SETTING: The Whitehall II study. PARTICIPANTS: 4469 British civil servants (72% men) aged 39-62 years at baseline. MAIN OUTCOME MEASURE: Change in LDL-cholesterol concentrations between the baseline (1991-3) and follow-up (2003-4). RESULTS: Mean LDL-cholesterol decreased from 4.38 to 3.52 mmol/l over a mean follow-up of 11.3 years. In a mutually adjusted model, a decline in LDL-cholesterol was greater among those who were taking lipid-lowering treatment at baseline (-1.14 mmol/l, n=34), or started treatment duri...
AbstractCardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximat...
Low density lipoprotein cholesterol (LDL-C) is theappropriate focus of primary and secondary preven-...
BACKGROUND: Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >= 190 m...
International audienceOBJECTIVE: To examine the association of lipid-lowering drugs, change in diet ...
In 2015, the Dietary Guidelines for Americans (DGA) eliminated the historical upper limit of 300 mg ...
AIM: Decreasing cholesterol levels in Western populations is the main reason for decreasing mortalit...
This case-study presents data supporting the use of a combination of a lipid-lowering diet and physi...
Lowering elevated levels of low-density lipoprotein cho-lesterol (LDL-C) is a surefire way to reduce...
Background -Patients with primary elevations of LDL-C ≥190 mg/dL are at a higher risk of atheroscler...
AIMSTo evaluate the impact of lipid-lowering treatment on cholesterol concentrations in the setting ...
AbstractSince the first epidemiological evidence on the benefit of lipid reduction in coronary heart...
Aims To review the importance of lipid parameters beside low-density lipoprotein (LDL) levels as ris...
OBJECTIVES: To describe low-density lipoprotein (LDL) cholesterol management and lipid-lowering trea...
AbstractThe West of Scotland Coronary Prevention Study (WOSCOPS), a placebo-controlled 5-year cohort...
Objectives: Elevated blood cholesterol is a modifiable risk factor for cardiovascular disease. Chol...
AbstractCardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximat...
Low density lipoprotein cholesterol (LDL-C) is theappropriate focus of primary and secondary preven-...
BACKGROUND: Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >= 190 m...
International audienceOBJECTIVE: To examine the association of lipid-lowering drugs, change in diet ...
In 2015, the Dietary Guidelines for Americans (DGA) eliminated the historical upper limit of 300 mg ...
AIM: Decreasing cholesterol levels in Western populations is the main reason for decreasing mortalit...
This case-study presents data supporting the use of a combination of a lipid-lowering diet and physi...
Lowering elevated levels of low-density lipoprotein cho-lesterol (LDL-C) is a surefire way to reduce...
Background -Patients with primary elevations of LDL-C ≥190 mg/dL are at a higher risk of atheroscler...
AIMSTo evaluate the impact of lipid-lowering treatment on cholesterol concentrations in the setting ...
AbstractSince the first epidemiological evidence on the benefit of lipid reduction in coronary heart...
Aims To review the importance of lipid parameters beside low-density lipoprotein (LDL) levels as ris...
OBJECTIVES: To describe low-density lipoprotein (LDL) cholesterol management and lipid-lowering trea...
AbstractThe West of Scotland Coronary Prevention Study (WOSCOPS), a placebo-controlled 5-year cohort...
Objectives: Elevated blood cholesterol is a modifiable risk factor for cardiovascular disease. Chol...
AbstractCardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximat...
Low density lipoprotein cholesterol (LDL-C) is theappropriate focus of primary and secondary preven-...
BACKGROUND: Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >= 190 m...